Endocrine Abstracts

Background: Pituitary adenomas (PA) and pheochromocytomas/paraganglioma (pheo/PGL) can occur in the same patient due to coincidence or of shared pathogenesis. There is evidence that, at least in some cases, classical pheo/PGL predisposing genes, may also play a role in pituitary tumorigenesis. A new condition called ‘the three P Association’ (3PAs) for the combination of PA with pheo/PGL has been recently described in patients with or without succinate dehydrogenase ...

Context: Ipilimumab is a human monoclonal antibody against cytotoxic T lymphocyte antigen-4 (CTLA-4), which enhances stimulation of cytotoxic T lymphocytes, resulting in an immune response against the tumour. This drug-induced hyperactivity of the immune system can lead to serious adverse effects including endocrine disorders such as autoimmune hypophysitis, thyroiditis and adrenal insufficiency.Objective: To report our experience on ipilimumab-induced h...

Introduction: Pheochromocytomas (Pheo) may appear sporadically (SPheo) or as an autosomal dominant inherited disease, named as familial PHEOs (FPheo). The latter are present in younger patients, and usually with multiple tumors, but may occur in patients with apparently simple sporadic tumors with no other syndromic features.Material and methods: Clinical data of all consecutive patients underwent surgery for Pheo over 35 years in two tertiary referral c...

Introduction: Bariatric surgery is an effective therapy for patients with type 2 diabetes mellitus (T2D). Many mechanisms have been proposed for its metabolic benefits, such as caloric restriction, weight loss, increased secretion of gut hormones like glucagon-like peptide 1 (GLP-1) and 2 (GLP-2), bile acid diversion, decrease of pancreatic and hepatic fat deposits and changes in gut microbiome.Aims: Evaluate changes after surgery in gut microbiome profi...

Background: Individuals with neurofibromatosis type-1 (NF1) carry an increased risk of pheochromocytoma (PHEO). Detection strategy is unknown but most experts recommend screening if hypertension develops.Objective: Report the characteristics of PHEO in patients with NF1 (NF1 group) and compare them with non-NF1-associated PHEO (non-NF1 group).Methods: Retrospective cohort study of patients undergoing PHEO resection in two Spanish t...

Background: Pituitary adenomas (PA) and pheochromocytomas/paragangliomas (PCC/PGL) are the main components of MEN1 and MEN2, respectively. Although the presence of both tumors (3P association, 3PAs) in the same patient could be as a result of coincidence, at least in some cases, a common pathogenic mechanism has been involved. Recently has been confirmed that germline mutations in genes coding succinate dehydrogenase (SDH) play a role in pituitary tumorigenesis. Furthermore, M...

Background: The 2017 World Health Organization classification of pituitary tumors established that, pituicytoma, granular cell tumor of the sella (GCT) and spindle cell oncocytoma (SCO) are posterior pituitary tumors (PPT). These lesions are non-neuroendocrine and low-grade neoplasms of the sellar region presenting with mass effect symptoms. Their clinical manifestation, hormonal profile and radiological findings are indistinguishable from non-functioning pituitary adenomas (N...

Background: Adrenocortical carcinoma (ACC) is a rare and aggressive neoplasm with a 5-year survival rate <30%. Survival depends mainly on the stage at diagnosis, being surgery the only curative treatment.Objective: To report the clinical features, management and outcomes of a series of ACC in two Spanish tertiary hospitals.Material and methods: All patients with pathological diagnosis of ACC between 2000 and 2017 were included ...

Introduction: Current guidelines propose temozolomide (TMZ) as the first-line chemotherapy for aggressive pituitary neuroendocrine tumors (PitNETs), but no clinical trials have been conducted and clinical experience in this context is limited.Patients and methods: A retrospective study of patients with aggressive pitNETs treated with TMZ was conducted by the members of the Neuroendocrinology Working Area of the Spanish Society of Endocrinology and Nutrit...

Introduction: Primary tumours in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.Aims: Evalu...